BELITE BIO INC - ADR
BLTENASDAQ🏆 #898 by market capEarnings Aug 13 · PostUS Equity
$176.59▲ $11.55 (+6.54%)
Live1h—
24h▲ 6.5%
7d▲ 12.4%
14d▲ 13.4%
30d▲ 18.3%
1y▲ 154.0%
🏦Market Cap
$7.08B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
42
Weak
Trading Snapshot
- Day Range
- $174.44 – $178.05
- 52-Week Range
- $59.12 – $200.00
- Volume
- $2.13B
- Avg Volume
- $2.40B
- Shares Outstanding
- 40.1M
- Next Earnings
- Oct 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $610M
- Last Q Revenue
- $140M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.65
- Dividend Yield
- —
Why Investors Own BLTE
- ✓High-growth profile — revenue up +46.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$610M▲ +43.3% YoY
Gross Margin (TTM)
46.5%▲ +1.7% YoY
Operating Income (TTM)
$215M▲ +43.3% YoY
Free Cash Flow (TTM)
$133M▲ +43.3% YoY
About BELITE BIO INC - ADR
A company profile for BELITE BIO INC - ADR isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
42/100
Analyst Ratings
ⓘConsensus
Buy
14 analysts
Strong Buy4
Buy9
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026
Latest News & Updates
SeekingAlpha·13d ago
Belite Bio: The Oral Route Is The Real Competitive Moat
Belite Bio (BLTE) is positioned for upside with tinlarebant, an oral therapy for Stargardt disease, following a successful Phase 3 DRAGON trial and NDA...
Benzinga·22d ago
Why Is Belite Bio Stock Gaining Monday?
Belite Bio (BLTE) stock jumps 3% on positive Phase 3 DRAGON trial data for its Stargardt disease drug candidate tinlarebant.
🌌
Benzinga·22d ago
Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In Montréal
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growthPresentation to include positive update on